RecruitingNCT06725719

Translocator Protein PET/CT in Various TSPO-Related Disease


Sponsor

Tianjin Medical University

Enrollment

200 participants

Start Date

Nov 1, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

To evaluate the potential usefulness of 18F-DPA714/FDPA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various TSPO-related disease patients.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying 18F-DPA714/FDPA for people with neurodegenerative diseases, neuroinflammation, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST18F-DPA714/FDPA

Each subject receive a single intravenous injection of 18F-DPA714/FDPA, and undergo PET/CT or MRI imaging within the specificed time.


Locations(3)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06725719


Related Trials